These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

205 related items for PubMed ID: 18294113

  • 1. Iron overload disorders: treatment options for patients refractory to or intolerant of phlebotomy.
    Bring P, Partovi N, Ford JA, Yoshida EM.
    Pharmacotherapy; 2008 Mar; 28(3):331-42. PubMed ID: 18294113
    [Abstract] [Full Text] [Related]

  • 2. Iron mobilization using chelation and phlebotomy.
    Flaten TP, Aaseth J, Andersen O, Kontoghiorghes GJ.
    J Trace Elem Med Biol; 2012 Jun; 26(2-3):127-30. PubMed ID: 22565013
    [Abstract] [Full Text] [Related]

  • 3. Iron chelation therapy for patients with sickle cell disease and iron overload.
    Inati A, Khoriaty E, Musallam KM, Taher AT.
    Am J Hematol; 2010 Oct; 85(10):782-6. PubMed ID: 20721892
    [No Abstract] [Full Text] [Related]

  • 4. Management of transfusion-related iron overload in patients with myelodysplastic syndromes.
    Shah J, Kurtin SE, Arnold L, Lindroos-Kolqvist P, Tinsley S.
    Clin J Oncol Nurs; 2012 Jun; 16 Suppl():37-46. PubMed ID: 22641283
    [Abstract] [Full Text] [Related]

  • 5. Novel treatment options for transfusional iron overload in patients with myelodysplastic syndromes.
    Goldberg SL.
    Leuk Res; 2007 Dec; 31 Suppl 3():S16-22. PubMed ID: 18037414
    [Abstract] [Full Text] [Related]

  • 6. Daily alternating deferasirox and deferiprone therapy for "hard-to-chelate" beta-thalassemia major patients.
    Balocco M, Carrara P, Pinto V, Forni GL.
    Am J Hematol; 2010 Jun; 85(6):460-1. PubMed ID: 20513129
    [No Abstract] [Full Text] [Related]

  • 7. Iron burden and liver fibrosis decrease during a long-term phlebotomy program and iron chelating treatment after bone marrow transplantation.
    Meo A, Ruggeri A, La Rosa MA, Zanghì L, Morabito N, Duca L.
    Hemoglobin; 2006 Jun; 30(1):131-7. PubMed ID: 16540426
    [Abstract] [Full Text] [Related]

  • 8. Deferasirox in patients with iron overload secondary to hereditary hemochromatosis: results of a 1-yr Phase 2 study.
    Cançado R, Melo MR, de Moraes Bastos R, Santos PC, Guerra-Shinohara EM, Chiattone C, Ballas SK.
    Eur J Haematol; 2015 Dec; 95(6):545-50. PubMed ID: 25684349
    [Abstract] [Full Text] [Related]

  • 9. Iron chelation therapy in the management of transfusion-related cardiac iron overload.
    Fernandes JL.
    Transfusion; 2012 Oct; 52(10):2256-68. PubMed ID: 22404719
    [Abstract] [Full Text] [Related]

  • 10. Chelation therapy for iron overload.
    Barton JC.
    Curr Gastroenterol Rep; 2007 Mar; 9(1):74-82. PubMed ID: 17335681
    [Abstract] [Full Text] [Related]

  • 11. Review article: the iron overload syndromes.
    Siddique A, Kowdley KV.
    Aliment Pharmacol Ther; 2012 Apr; 35(8):876-93. PubMed ID: 22385471
    [Abstract] [Full Text] [Related]

  • 12. Recent developments in iron chelation therapy.
    Cario H, Janka-Schaub G, Janssen G, Jarisch A, Strauss G, Kohne E.
    Klin Padiatr; 2007 Apr; 219(3):158-65. PubMed ID: 17525910
    [Abstract] [Full Text] [Related]

  • 13. Objectives and mechanism of iron chelation therapy.
    Hershko C, Link G, Konijn AM, Cabantchik ZI.
    Ann N Y Acad Sci; 2005 Apr; 1054():124-35. PubMed ID: 16339658
    [Abstract] [Full Text] [Related]

  • 14. Introduction of higher doses of deferasirox: better efficacy but not effective iron removal from the heart and increased risks of serious toxicities.
    Kontoghiorghes GJ.
    Expert Opin Drug Saf; 2010 Jul; 9(4):633-41. PubMed ID: 20553089
    [Abstract] [Full Text] [Related]

  • 15. Iron overload and allogeneic hematopoietic stem-cell transplantation.
    Kanda J, Kawabata H, Chao NJ.
    Expert Rev Hematol; 2011 Feb; 4(1):71-80. PubMed ID: 21322780
    [Abstract] [Full Text] [Related]

  • 16. HJV hemochromatosis, iron overload, and hypogonadism in a Brazilian man: treatment with phlebotomy and deferasirox.
    Santos PC, Cançado RD, Pereira AC, Chiattone CS, Krieger JE, Guerra-Shinohara EM.
    Acta Haematol; 2010 Feb; 124(4):204-5. PubMed ID: 21071928
    [No Abstract] [Full Text] [Related]

  • 17. Iron-chelating therapy with the new oral agent ICL670 (Exjade).
    Cappellini MD.
    Best Pract Res Clin Haematol; 2005 Jun; 18(2):289-98. PubMed ID: 15737891
    [Abstract] [Full Text] [Related]

  • 18. Italian Society of Hematology practice guidelines for the management of iron overload in thalassemia major and related disorders.
    Angelucci E, Barosi G, Camaschella C, Cappellini MD, Cazzola M, Galanello R, Marchetti M, Piga A, Tura S.
    Haematologica; 2008 May; 93(5):741-52. PubMed ID: 18413891
    [Abstract] [Full Text] [Related]

  • 19. Iron overload in thalassemia and related conditions: therapeutic goals and assessment of response to chelation therapies.
    Porter JB, Shah FT.
    Hematol Oncol Clin North Am; 2010 Dec; 24(6):1109-30. PubMed ID: 21075283
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.